Kallyope
Neural signaling pathway-based therapeutic medicines for migraine and metabolic disorders
New patent ·
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2014
- Latest Form D
- $12.1M, Oct 2015
- Total capital
- $12.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $12.1M
- 1 Form D · last Oct 2015
- 132 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2022
- Rank in peer group#33 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$12.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#33 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Adam GoulburnExecutive Officer, DirectorNamed in SEC Form D filings
- Joshua WolfeDirectorNamed in SEC Form D filings
- Kenneth ClarkExecutive OfficerNamed in SEC Form D filings
- Michael O'DonnellExecutive OfficerNamed in SEC Form D filings
- Nancy ThornberryExecutive Officer, DirectorNamed in SEC Form D filings
- Terry McGuireDirectorNamed in SEC Form D filings
Show all 9 people
- Tim KutzkeyDirectorNamed in SEC Form D filings
- Tom ManiatisDirectorNamed in SEC Form D filings
- William RieflinDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 40- New patentCompositions For Treating Or Preventing PainUSPTOUS 12,766,136
- PendingCombination TherapiesUSPTOApplication 18874815
- PendingPeptide Analogs And Methods Of Using The SameUSPTOApplication 19415046
Show all 40 patent records
- Compositions For Treating Or Preventing PainOct 20, 2026 · US 12,766,136Granted
- Combination TherapiesJul 9, 2026 · Application 18874815Pending
- Peptide Analogs And Methods Of Using The SameJun 25, 2026 · Application 19415046Pending
- Compositions For Treating Or Preventing PainApr 23, 2026 · Application 19364247Pending
- GPR40 AgonistsSep 4, 2025 · Application 19042316Pending
- Treatment Of Headache Disorders With NK3 ModulatorsAug 28, 2025 · Application 18859693Pending
- NK3 Modulators And Uses ThereofAug 21, 2025 · Application 19024446Pending
- NK3 Modulators And Uses ThereofApr 22, 2025 · US 12,281,114Granted
- GPR40 AgonistsApr 1, 2025 · US 12,264,171Granted
- Compositions Comprising 4-({(4-CYCLOPROPYLISOQUINOLIN-3-YL)[4-(TRIFLUOROMETHOXY)BENZYL]AMINO}SULFONYL)BENZOIC Acid And Methods Of Use ThereofFeb 20, 2025 · Application 18824168Pending
- GPR119 AgonistsJul 4, 2024 · Application 18285812Pending
- Combination TherapiesApr 11, 2024 · Application 18387170Pending
- Ampk ActivatorsMar 28, 2024 · Application 18386084Pending
- Ampk ActivatorsDec 26, 2023 · US 11,851,429Granted
- GPR40 AgonistsMay 18, 2023 · Application 17802910Pending
- SSTR5 AntagonistsApr 13, 2023 · Application 17782438Pending
- GPR119 AgonistsMar 2, 2023 · Application 17875776Pending
- SSTR5 AntagonistsFeb 16, 2023 · Application 17782370Pending
- SSTR5 AntagonistsFeb 9, 2023 · Application 17782361Pending
- GPR119 AgonistsNov 29, 2022 · US 11,512,065Granted
- Ampk ActivatorsOct 27, 2022 · Application 17846819Pending
- Ampk ActivatorsAug 9, 2022 · US 11,407,768Granted
- GPR40 AgonistsJul 21, 2022 · Application 17614100Pending
- Gpcr Combination TherapiesMay 19, 2022 · Application 17440901Pending
- Ampk ActivatorsMar 22, 2022 · US 11,279,702Granted
- Compositions For Treating Or Preventing Vasomotor SymptomsJun 17, 2021 · Application 17187769Pending
- Methods Of Making A GPR40 AgonistApplication 63613884Pending
- NK3 Modulators And Uses ThereofApplication PCTUS2024024989Pending
- NK3 Modulators And Uses ThereofApplication PCTUS2024024991Pending
- Combination Therapy For Treatment Of Metabolic DiseaseApplication 63613964Pending
- GPR40 AgonistsApplication PCTUS2024060486Pending
- Peptide Analogs And Methods Of Using The SameApplication PCTUS2025027364Pending
- Ampk ActivatorsApplication 63111837Pending
- GPR40 AgonistsApplication 63117074Pending
- Combination Therapy For Treatment Of Metabolic DiseaseApplication PCTUS2024061080Pending
- NK3 Modulators And Uses ThereofApplication PCTUS2024024994Pending
- Peptide Analogs And Methods Of Using The SameApplication 63641660Pending
- Crystalline GPR40 Agonist And Methods Of MakingApplication PCTUS2024061074Pending
- Compositions For Treating Or Preventing PainApplication 63894983Pending
- NK3 Modulators And Uses ThereofApplication PCTUS2024050690Pending
Related companies, and why
- VISTERRA, INC.Similar federal contract value in Biotech · null in contracts
- Noema PharmaSimilar federal contract value in Biotech · null in contracts
- Cerium Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Ashvattha Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- PALATIN TECHNOLOGIES INCSimilar federal contract value in Biotech · null in contracts
- BioIncept, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .